Özde Nisa Türkkan

Özde Nisa Türkkan

Auto-generated profile, based on publicly available information

Özde Nisa Türkkan

Department of Pediatric Nephrology, Marmara University Faculty of Medicine, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
MTMehmet Taşdemir
Mehmet Taşdemir
NCNur Canpolat
Nur Canpolat
NYNurdan Yildiz
Nurdan Yildiz
GÖGül Özçelik
Gül Özçelik
MBMeryem Benzer
Meryem Benzer
IBIlmay Bilge
Ilmay Bilge
Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or -resistant) and the dosing regimen. Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m(2)) or high (2-4 doses of 375 mg/m(2)) initial dose of rituximab and the steroid response. Clinical outcomes were compared. Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9-17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 +/- 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups. Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.

4 March 2026 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
NCNeslihan Cicek
Neslihan Cicek
CACeren Alavanda
Ceren Alavanda
APAyse Seda Pınarbası
Ayse Seda Pınarbası
AIAylin Inal
Aylin Inal
BABahriye Atmıs
Bahriye Atmıs
IGIbrahim Gokce
Ibrahim Gokce
Introduction: We aimed to evaluate the clinical and genetic characteristics and clinical course of children with persistent proteinuria associated with CUBN variants. Methods: Forty-eight children with CUBN variants from 15 pediatric nephrology centers were included. Patients’ characteristics, serum creatinine, albumin, hemoglobin, vitamin B12 levels, urinalysis, spot urine protein/creatinine (uPCR), microalbumin/creatinine (uACR), beta-2 microglobulin/creatinine (uBMCR) ratios, estimated glomerular filtration rates (eGFRs), treatments, kidney biopsies, and genetic findings were evaluated. Results: All patients had normal serum albumin and creatinine and preserved eGFR. There was no significant change in eGFR between the first and last visits ( p = 0.15), whereas uPCR was lower at the last visit ( p = 0.001). Kidney biopsy was performed in 13 (27%); light microscopy was normal in all except one patient with focal segmental glomerulosclerosis (FSGS). Thirty-five patients (72.9%) had ACEi/ARB therapy, which was discontinued in 21 patients without subsequent worsening of proteinuria. Overall, 26 distinct CUBN variants were identified, predominantly in the C-terminal region. The most frequent variant was c.10102A > G (p.Met3368Val). Variant types included 15 (57.7%) missense, 7 (27%) nonsense, 3 (11.5%) splicing, and 1 (3.8%) frameshift variants. Conclusions: In this multicenter, large pediatric cohort, proteinuria associated with CUBN variants generally followed a benign course over short to mid-term follow-up even without sustained ACEi/ARB therapy. Embedding targeted CUBN testing into the evaluation of children with asymptomatic proteinuria and normal kidney function may reduce unnecessary kidney biopsies and prolonged medication, while improving family counseling. We outline a stepwise care pathway → early genetic screening → conservative monitoring with periodic eGFR and proteinuria assessment → consideration of ACEi/ARB discontinuation and recommend prospective validation and cost-effectiveness studies.

26 August 2026 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
YAYeşim Özdemir Atikel
Yeşim Özdemir Atikel
SESEVCAN AZIME BAKKALOGLU EZGU
SEVCAN AZIME BAKKALOGLU EZGU
AYAlev Yilmaz
Alev Yilmaz
ATAslı Çelebi Tayfur
Aslı Çelebi Tayfur
ATAslı Kavaz Tufan
Aslı Kavaz Tufan
RTRezan Topaloglu
Rezan Topaloglu
Background: Nephropathic cystinosis is a rare multisystem disorder in which transition from pediatric to adult care is particularly a vulnerable period because of lifelong treatment demands and the need for sustained multidisciplinary follow-up. We aimed to assess awareness, perceptions, and self-reported transition practices among pediatric nephrologists in Türkiye caring for patients with nephropathic cystinosis. Methods: We conducted a nationwide descriptive cross-sectional web-based survey of pediatric nephrologists in Türkiye who had longitudinally followed at least one patient with nephropathic cystinosis. A 59-item questionnaire covering awareness, perceptions, and self-reported practices was administered via Google Forms, and responses were analysed descriptively at the item level. Results: In this nationwide descriptive cross-sectional web-based survey, 48 pediatric nephrologists participated. Respondents worked mainly in university hospitals (47.9%) and training and research hospitals (39.6%) and had a median of 14 years of pediatric nephrology experience (IQR 6–17). Although 66.7% distinguished transition from transfer, familiarity with cystinosis-specific transition models was limited; only 16.7% had ever applied a structured model and 8.3% reported a written transition plan in their center. The most frequently perceived challenges were treatment non-adherence (89.6%) and disruption of multidisciplinary follow-up (87.5%). Most respondents reported marked differences between pediatric and adult services, and the median recommended age for initiating transition planning was 17.5 years (IQR 17–18). Overall, 91.7% supported the development of a national transition model (58.3% considered it definitely necessary and 33.3% necessary but difficult to implement without external support). Conclusions: Among pediatric nephrologists in Türkiye, awareness of transition-related risks in nephropathic cystinosis was high, but structured transition practices were uncommon and initiation of transition planning was generally recommended at a later age than suggested by current guidance. These findings indicate an implementation gap and support the development of a feasible national transition framework that can be adapted to local resources.

1 April 2023
Verified
Book
Open access
PDF file
YGYahya Gül
Yahya Gül
ŞKŞeyhan Kutluğ
Şeyhan Kutluğ
EDEsra Dişçi
Esra Dişçi
BYBahtınur Yener
Bahtınur Yener
MCMahmut Cesur
Mahmut Cesur
GKGülizar Koç
Gülizar Koç
Ömrünü eğitime ve tıp bilimine adamış, pediatri alanında kendi eğitimini tamamlayan ve hala sürdüren yazarlarımız ile iki yıldır süren çalışmalarımızın meyvesi olan kitabımız için çok mutluyuz. Yedi yaşından beri gece gündüz demeden çalışan, pediatri uzmanlığını ve yan dalını hakkıyla tamamlamak için çok emek harcayan arkadaşlar, tecrübelerini ve öğrendiklerini eğitime yeni başlayan meslektaşlarına aktarmak için bir kılavuz olacak bu kitabı hazırladık. Bu kitabın; pratisyen hekim, pediatri asistanları ve uzmanlarına klinik pratikte en sık karşılaşacakları hastalıkların tanısı, kliniği ve tedavisi konusunda hızlıca bilgilere ulaşabilmeleri açısından çok büyük kolaylık sağlayacağına inanıyoruz. Bu nedenle acillerde, polikliniklerde ve servislerde sıkça başvurulan bir kitap olacağını düşünüyoruz.

1 January 2023 in OSMANGAZİ JOURNAL OF MEDICINE
Verified
Journal Article
Open access
PDF file
BABagdagul Aksu
Bagdagul Aksu
ZYZeynep Yuruk Yi̇ldi̇ri̇m
Zeynep Yuruk Yi̇ldi̇ri̇m
AYAlev Yilmaz
Alev Yilmaz
CPCemile Pehlivanoglu
Cemile Pehlivanoglu
ÖTÖzde Nisa Türkkan
Özde Nisa Türkkan
SESevinç Emre
Sevinç Emre
Hipertansiyon (HT), çocuklarda giderek artan önemli bir sağlık sorunudur. Son 20 yıl içinde çevresel ve sosyal faktörlerdeki değişiklikler, daha az fiziksel aktivite, hızlı beslenme alışkanlıkları, obezite ve metabolik sendrom, HT gelişimini doğrudan etkilemektedir. Çalışmamızın amacı, 18 yıllık bir süreçte HT tanısıyla izlenen çocuklarda yıllar içinde obezite ve metabolik sendrom sıklığının artıp artmadığını belirlemektir. Ocak 2001-Aralık 2018 tarihleri arasında Çocuk Nefroloji Polikliniği’nde HT nedeni ile başvuran ve HT tanısı kesinleşen 377 hasta retrospektif olarak değerlendirildi. Hastalar, 2001-2009 döneminde başvuran hastalar (Grup I) ve 2010-2018 döneminde başvuran hastalar (Grup II) olmak üzere iki gruba ayrıldı ve iki grup obezite ve metabolik sendrom açısından karşılaştırıldı. Ortalama başvuru yaşı 11,4±4,5 yıldı. Hastaların %64’ü erkekti. Grup 2’deki hastaların yaş, VKİ, metabolik sendrom ve ailede hipertansiyon olma öyküsü Grup 1’den yüksekti. İki grup arasında obezite açısından fark yoktu (p>0,05). Çalışmamızın sonuçları, hipertansiyon tanısıyla izlediğimiz hastalarda son yıllarda 2009 ve öncesine göre hem VKİ’de hem de metabolik sendrom görülme oranında artış olduğunu göstermiştir. Bu değişiklikler, özellikle ergenlerde belirgindir. Çocuk ve ergenlerde sodyum alımının azaltılması ve yaşam tarzı değişikliği önerileriyle obezitenin önlenmesi, HT gelişiminin engellemesi ve tedavisinde ilk aşamayı oluşturur.

29 January 2025 in Marmara Medical Journal
Verified
Journal Article
Open access
PDF file
KKKıvılcım Cerit Karadeniz
Kıvılcım Cerit Karadeniz
NENursah Eker
Nursah Eker
AAAhsen Karagözlü Akgül
Ahsen Karagözlü Akgül
DGDilek Gül
Dilek Gül
ÖTÖzde Nisa Türkkan
Özde Nisa Türkkan
GKGürsu Kıyan
Gürsu Kıyan
Objective: Desmoplastic small round cell tumor (DSRCT) is a rare form of highly aggressive sarcoma and despite multimodal therapy, mortality still remains high. The aim of the study is to review our experience in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in children with DSRCT. Patients and Methods: A retrospective review of patients with DSRCT followed in our institution between January 2020-January 2024 was performed. Demographics, radiological imaging, histopathology results, cytogenetic analyses, chemotherapy/radiotherapy protocols, operative data and outcomes were analyzed. Results: Three patients with DSRCT were identified. The median age was 13.3 years (12-16 years). HIPEC was performed after CRS in two patients, while HIPEC procedure could not be applied in one patient with unresectable tumor. One patient underwent reoperation/re-HIPEC for recurrence after seven months. One patient had the diagnosis after complete removal of the tumor. Patient required peritonectomy and HIPEC as a second operation due to peritoneal recurrence. The patients who underwent CRS and HIPEC are still alive for 33 and 34 months since initial diagnosis, nevertheless the patient who had an unresectable tumor died after 8 months. Conclusion: Cytoreductive surgery and HIPEC may be considered as a safe and feasible treatment option in children with DSRCT in experienced centers.